Josh Meier

Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem

Josh Meier, Matt McPartlon, Pat Grady, Sonali Singh

Chai Discovery is industrializing drug discovery by deploying a simplified, AI-driven infrastructure that replaces traditional trial-and-error with scalable molecule design, partnering with major pharmaceutical firms like Eli Lilly and Pfizer rather than managing a full internal pipeline. The company's second-generation model has achieved a 15% binding success rate through diffusion-based generation and a continuous feedback loop from wet-lab experiments, effectively targeting historically undruggable biological structures. By shifting the industry toward computational "last in class" solutions, Chai aims to accelerate development timelines from months to days while ensuring extreme safety and manufacturability at the molecular generation stage.